On January 22, 2024, Outlook Therapeutics reached an agreement with the holder of its outstanding convertible promissory note to extend the maturity until July 1, 2025, subject to certain conditions, including receipt of at least $25.0 million of proceeds from an equity offering and reduction of the conversion price on $15.0 million aggregate principal amount of the note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OTLK:
- Outlook Therapeutics price target raised to $2 from $1.50 at Ascendiant
- Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls
- Outlook Therapeutics upgraded at Capital One after ‘great feedback’ from FDA
- Outlook Therapeutics upgraded to Overweight from Equalweight at Capital One
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
